Replies to post #24197 on NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

Normally a good idea. Just don't miss the upcoming HE PR.

[longusa]

gnawkz, a few comments on cash position:
The 10Q says:

2. Liquidity and Financial Condition

During the nine months ended September 30, 2014, the Company used approximately $36.0 million of cash in its operating activities including one-time expenditures relating to the clinical trials and to certain initial costs for new manufacturing capacity in Europe. The Company incurred an aggregate combined cash and non-cash loss of $92.9 million for the nine months ended September 30, 2014, including $37.8 million of non-cash charges associated with stock based compensation, a mark to market charge for the change in the fair value of its derivative liability, and inducement expenses related to the exchange of Cognate accounts payable for common stock and warrants.

and

During the quarter ended September 30, 2014, the Company issued an aggregate of 497,133 shares of common stock from the exercise of warrants previously issued. The Company received proceeds of $1.7 million from the exercise of these warrants.

That's a burn of 4m/mo. So add to the 36m expended, 21m for the UK facility and 6m for 6 weeks of Q4 and the cash balance as of this week should be approx. 79m+1.7m-36m-21m-6m = 17.7m